Delta-tetrahydrocannabinol (THC), the active compound in marijuana has been found to cut tumor growth by half in common lung cancer, aside from significantly reducing the ability of the cancer to spread.
Conducted by researchers at Harvard University, this is the first study to demonstrate that a cannabinoid compound inhibits EGF-induced growth and migration in epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer cell lines.
According to Anju Preet, Ph.D., a researcher in the Division of Experimental Medicine:
“The beauty of this study is that we are showing that a substance of abuse, if used prudently, may offer a new road to …read more

A product of GlaxoSmithKile Plc – TYKERB® (lapatinib) – has recently been approved by the USFDA, in combination with Xeloda® (capecitabine), for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
TYKERB® (a pdf file) – a small molecule that inhibits the tyrosine kinase components of the EGFR (ErbB1) and HER2 (ErbB2) receptors – is the first targeted, once-daily oral treatment option for the abovementioned patient population.
This approval reflects more than 16 years of research, including more than 60 clinical trials and investigator-initiated …read more